Page 12 - AN-3-2
P. 12

Advanced Neurology                                                Limbic-predominant TDP-43 encephalopathy



            compared to remote memory) and slow and progressive   clinical data suggesting the existence of synucleinopathy).
                                                                                                             5
            involvement of other cognitive domains in dementia   There are also non-mandatory supportive criteria,
            stages. 5,8,26,46  Therefore, it  is not  surprising  that LATE  is   including: (i) clinical factors (patient age equal to or greater
            part of the potential differential diagnosis of AD. 11,29,39    than 75 years; relatively preserved neocortical functions;
            However, it is worth noting that pure cases of LATE affect   the presence of semantic memory impairment in early
            individuals of more advanced age compared to pure cases   stages of the disease); (ii) structural (disproportionate
            of AD or cases with co-pathology of AD and LATE. In   hippocampal  atrophy  in  MRI)  and  functional
            addition, LATE cases have a more benign clinical course   neuroimaging criteria (FDG-PET [fluorodeoxyglucose-
            with a slower progression of amnestic cognitive decline.    positron emission tomography] hypometabolism in the
                                                          9
            Therefore, the diagnosis of possible LATE should be   limbic system without a characteristic pattern of AD); and
            considered, to be confirmed through anatomopathological   (iii) low likelihood of significant neocortical tau pathology
            study, in individuals with a typical clinical syndrome of   (confirmation of low probability of AD pathology assessed
            AD (predominantly amnestic MCI), a negative core AD   through ATN biomarkers in CSF or amyloid PET).  The
                                                                                                         52
            biomarker study, advanced age, and in the absence of   degree of diagnostic certainty is established based on
            another potential alternative etiological diagnosis.  the number of supportive criteria met in addition to the
              The main challenge in achieving an early and accurate   mandatory criterion of amnestic-predominant cognitive
            diagnosis of LATE lies in the absence of validated clinical   decline.
            criteria for use in clinical practice and the lack of reliable   In addition to the predominantly amnestic cognitive
            biomarkers  (Figure 2). Recently, a proposal has emerged   decline, researchers have explored whether other
                     5
            to establish the diagnosis of LANS (limbic-predominant   behavioral or motor symptoms are more or less prevalent
            amnestic neurodegenerative syndrome), which would also   in individuals diagnosed with LATE.  However, the
                                                                                                13
            suggest LATE, although it would not be specific to it.  The   results regarding behavioral symptoms are inconsistent to
                                                      52
            diagnosis of LANS requires the presence of insidious, slowly   date. 34,35  One study suggests that cases of pure LATE-NC
            progressive cognitive decline over 2 or more years, with a   have  a  slightly  higher  risk  of  developing  behavioral
            clear amnestic predominance, and the absence of other   symptoms associated with the frontal lobe, while pure
            identifiable causes to justify it (including the absence of   AD cases exhibit a mild increase in the risk of agitation;


































            Figure 2. Typical clinical features of a patient with possible pure limbic-predominant age-related TDP-43 encephalopathy. Image created using Biorender.
            com
            Abbreviations: AT(N): Amyloid, tau, and neurodegeneration; CSF: Cerebrospinal fluid; FDG-PET: Fluorodeoxyglucose-positron emission tomography;
            MRI: Magnetic resonance imaging.


            Volume 3 Issue 2 (2024)                         6                                doi: 10.36922/an.2603
   7   8   9   10   11   12   13   14   15   16   17